botulinum toxin Type A (44U) — Competitive Intelligence Brief

botulinum toxin Type A (44U) (botulinum toxin Type A (44U)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuromodulator. Area: Neurology.

phase 3 Neuromodulator Acetylcholine release Neurology Biologic

Target snapshot

botulinum toxin Type A (44U) (botulinum toxin Type A (44U)) — Allergan. Botulinum toxin Type A (44U) works by blocking the release of acetylcholine, a neurotransmitter that causes muscle contraction.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
botulinum toxin Type A (44U) TARGET	botulinum toxin Type A (44U)	Allergan	phase 3	Neuromodulator	Acetylcholine release
Magnesium Sulfate	Magnesium Sulfate	Pfizer	marketed	Electrolyte; anticonvulsant	Neuromuscular junction; motor nerve impulse; acetylcholine release	1981-01-01
Botox infiltration	Botox infiltration	University Rovira i Virgili	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosome-associated protein); acetylcholine release machinery
Botulinum Toxin A (Botox )	Botulinum Toxin A (Botox )	Assistance Publique - Hôpitaux de Paris	marketed	Neurotoxin; acetylcholine release inhibitor	SNARE proteins (specifically SNAP-25); acetylcholine release machinery
Intradetrusor Botox Injections	Intradetrusor Botox Injections	The Methodist Hospital Research Institute	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosomal-associated protein); acetylcholine release machinery
Botulinum toxin A "Botox Cosmetics"	Botulinum toxin A "Botox Cosmetics"	Croma-Pharma GmbH	marketed	Neurotoxin; acetylcholine release inhibitor	SNARE complex (synaptosome-associated protein); acetylcholine release machinery
PrabotulinumtoxinA-Xvfs	PrabotulinumtoxinA-Xvfs	Lupo Center for Aesthetic and General Dermatology	marketed	Botulinum toxin type A	SNARE complex (acetylcholine release machinery)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuromodulator class)

1. Allergan · 1 drug in this class